Home  |  Contact

Cellosaurus 253J (CVCL_7935)

[Text version]

Cell line name 253J
Synonyms 253j; 253-J; 253 J; 253J-P; 253J-Parental; 253J P; 253JP
Accession CVCL_7935
Secondary accession CVCL_7938
Resource Identification Initiative To cite this cell line use: 253J (RRID:CVCL_7935)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: UBC-40 urothelial bladder cancer cell line index.
Population: Caucasian.
Doubling time: 36 hours (PubMed=66978; PubMed=748774); 46 +- 3 hours (PubMed=7658585); 28 hours (PubMed=3708594).
Microsatellite instability: Stable (MSS) (PubMed=31068700).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Bladder carcinoma (NCIt: C4912)
Derived from metastatic site: Retroperitoneal lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_7936 (253J laval )CVCL_7937 (253J-BV )CVCL_6G34 (253J-Lung-IV )
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): KCLB; PubMed=11416159; PubMed=27270441


Run an STR similarity search on this cell line
Web pages https://www.synapse.org/UC25

PubMed=4431054; DOI=10.1093/jnci/53.5.1341
Elliott A.Y., Cleveland P.H., Cervenka J., Castro A.E., Stein N., Hakala T.R., Fraley E.E.
Characterization of a cell line from human transitional cell cancer of the urinary tract.
J. Natl. Cancer Inst. 53:1341-1349(1974)

Elliott A.Y., Bronson D.L., Stein N., Fraley E.E.
In vitro cultivation of epithelial cells derived from tumors of the human urinary tract.
Cancer Res. 36:365-369(1976)

Elliott A.Y., Bronson D.L., Cervenka J., Cleveland P.H., Fraley E.E.
Establishment and characterization of epithelial cell cultures from tumors of the human urinary tract.
(In) Cell culture and the application; Acton R. (eds.); pp.711-728; Academic Press; New York (1977)

Elliott A.Y., Bronson D.L., Cervenka J., Stein N., Fraley E.E.
Properties of cell lines established from transitional cell cancers of the human urinary tract.
Cancer Res. 37:1279-1289(1977)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)

Elliott A.Y., Bronson D.L., Fraley E.E.
Transitional cell cancer: establishment and characterization of cell lines.
Natl. Cancer Inst. Monogr. 49:23-24(1978)

Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=7658585; DOI=10.1016/S0022-5347(01)66923-4
Dinney C.P.N., Fishbeck R., Singh R.K., Eve B., Pathak S., Brown N., Xie B., Fan D., Bucana C.D., Fidler I.J., Killion J.J.
Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.
J. Urol. 154:1532-1538(1995)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=11207054; DOI=10.1054/bjoc.2000.1641
Fujiyama C., Jones A., Fuggle S., Bicknell R., Cranston D., Harris A.L.
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Br. J. Cancer 84:558-564(2001)

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)

PubMed=26621286; DOI=10.1186/s12864-015-2227-4
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:1019.1-1019.2(2015)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cell line collections ATCC; HTB-108 - Discontinued
KCLB; 80001
Cell line databases/resources Cell_Model_Passport; SIDM01529
DepMap; ACH-000011
Anatomy/cell type resources BTO; BTO:0004796
Biological sample resources BioSample; SAMN10987961
Chemistry resources PharmacoDB; 253J_14_2019
Encyclopedic resources Wikidata; Q54583653
Gene expression databases ArrayExpress; E-MTAB-2770
GEO; GSM136240
GEO; GSM1574546
GEO; GSM1574574
Polymorphism and mutation databases Cosmic; 715794
Cosmic; 760476
Cosmic; 845564
Cosmic; 925827
Cosmic; 928820
Cosmic; 1016884
Cosmic; 1046680
Cosmic; 1082644
Cosmic; 1938694
Cosmic; 1285102
Cosmic; 1285997
Cosmic; 1927305
Cosmic; 2050426
Cosmic; 2057433
Cosmic; 2444255
Cosmic; 2685929
Cosmic; 2700994
IARC_TP53; 21034
LiGeA; CCLE_259
Entry history
Entry creation04-Apr-2012
Last entry update16-Dec-2021
Version number26